NEWS

Five-Year Retrospective Study Shows Topline Results for Patients Treated with Sensus Healthcare’s Superficial Radiation Therapy

Press Release



BOCA RATON, Fla.April 23, 2019 /PRNewswire/ — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in non-invasive treatments for both oncological and non-oncological conditions, announced today topline results from a five-year retrospective study of non-melanoma skin cancer (NMSC) patients treated with Superficial Radiation Therapy (SRT) (ClinicalTrials.gov Identifier: NCT03693937). The study, which was conducted across four U.S. sites, showed a 98.9 percent cure rate among 516 male and female patients. These patients had a collective total of 776 NMSC lesions treated with Sensus’ SRT-100™.

Most patients in the study population were elderly with a mean age of 79 years. Kaplan-Meier estimates of cumulative recurrence rates of all tumors at both 2 and 5 years were 1.1 percent; basal cell carcinoma cumulative recurrence rates at five years were 1.2 percent, and squamous cell carcinoma cumulative recurrence rates were 0.9 percent.  

“As we approach Skin Cancer Awareness Month in May, the results of this five-year study are not only timely and relevant but also show excellent cure rates,” said Dr. William Roth, lead investigator of the study and Voluntary Clinical Professor at The University of Miami School of Medicine, Department of Dermatology. “As the study confirms that SRT is a highly effective therapy, it’s critical that this modality be available, especially to patients who have comorbidities or advancing age.”

“SRT is a good option to offer patients with NMSC,” added Dr. Thomas Bender, dermatologist at Advanced Dermatology and Skin Care Centre, a Forefront Dermatology practice in Alabama. “We all have patients who aren’t good candidates for surgery, and patients feel empowered when they can choose their own therapy as opposed to only having surgery to treat their skin cancer.”

“These study results confirm what we’ve been hearing from our physicians,” concluded Isabelle Raymond, Ph.D., Vice President, Clinical Development, Sensus Healthcare. “Sensus is committed to advancing research and development for optimal SRT treatment to improve patient outcomes, and we look forward to presenting detailed study results at an upcoming scientific meeting.”      

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ robotic radiation oncology system provides targeted intraoperative triple-modulated radiotherapy (IORT) and Brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, with a single dose. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

Read the full press release here.

The Benefits of SRT

Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:

  1. 95%+ cure rates that rival surgery
  2. No anesthesia, cutting, bleeding, stitching or pain
  3. No downtime or lifestyle restrictions
  4. Super cosmesis, no unsightly scarring
  5. No need for post-treatment reconstructive surgeries